STAT

OCTOBER 9, 2023

The number of stroke deaths worldwide is set to climb 50% to nearly 10 million by 2050, with most cases occurring in low- and middle-income countries, according to a new wide-ranging report from the World Stroke Organization-Lancet Neurology Commission. The paper also projected that strokes will cause more disability worldwide, estimating that disability-adjusted life-years – the years of life lost and years living with stroke-induced disability – will grow about 30% to reach 190 m

308

308

PharmaVoice

OCTOBER 9, 2023

Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.

190

190

STAT

OCTOBER 9, 2023

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening. The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors.

289

289

PharmaVoice

OCTOBER 9, 2023

The leaders paving the way to pharma’s future with state-of-the-art digital solutions.

130

130

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

OCTOBER 9, 2023

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives. Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated.

282

282

Drug Patent Watch

OCTOBER 9, 2023

The article titled “Reviving an R&D Pipeline: A Step Change in the Phase II Success Rate” discusses Pfizer’s efforts to improve its research and development (R&D) productivity. The pharmaceutical industry… The post Reviving an R&D Pipeline appeared first on DrugPatentWatch - Make Better Decisions.

114

114

The Pharmacist

OCTOBER 9, 2023

A new working group has been set up to address disparities in attainment and awarding of degrees between Black trainee pharmacists and their White counterparts. The group, led by the Royal Pharmaceutical Society (RPS), also involves the British Pharmaceutical Students' Association (BPSA), the General Pharmaceutical Council (GPhC), NHS England (NHSE), Pharmacy Schools’ Council and representatives […] The post Working group to address differential attainment gap for Black trainees appeared f

95

95

STAT

OCTOBER 9, 2023

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.   There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

Biosimilars 215

Biosimilars Drug Development 215

Board Vitals - Pharmacist

OCTOBER 9, 2023

Several certifying boards, including the ABIM, have rolled out a new way for practitioners to maintain their certification. In addition to the traditional 10-year maintenance of certification (MOC) exam, the 5-year Longitudinal Knowledge Assessment (LKA) is available for many specialties. Despite its open-book format, the LKA should not be taken lightly.

105

105

Pharma Times

OCTOBER 9, 2023

The study will offer new insights into the immune system's response to iGAS - News - PharmaTimes

Immunity 127

Immunity Immunization Vaccines 127

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

European Pharmaceutical Review

OCTOBER 9, 2023

A new drug, part of a class of chemicals called potassium-channel openers, has demonstrated potential in offering relief to patients with focal epilepsy. Key data from a clinical trial, published in a report in JAMA Neurology, has revealed that adding the drug XEN1101 to a patient’s current antiseizure treatments saw a 33 percent to 53 percent drop in monthly seizures, depending on dose.

Dosage 95

Dosage 95

Pharma Times

OCTOBER 9, 2023

The agreement builds on the companies’s existing partnership - News - PharmaTimes

128

128

BioPharma Dive

OCTOBER 9, 2023

The purchase agreement with Chongqing Zhifei Biological Products is part of GSK’s plan to double sales of the shingles vaccine by 2026.

Vaccines 108

Vaccines 108

Express Pharma

OCTOBER 9, 2023

A study published in the journal Nature Communications has identified a new pathway that human immunodeficiency virus (HIV) uses to enter the nucleus of a healthy cell, where it can then replicate and go on to invade other cells. The researchers also identified three proteins that are needed for the virus to carry out the invasion and have in turn synthesised molecules (potential drugs) that can target one of the proteins, potentially leading to new treatments for AIDS. “ We have revealed a prot

Packaging 97

Packaging Communication Drug Development 97

European Pharmaceutical Review

OCTOBER 9, 2023

Bristol Myers Squibb ( BMS ) has agreed to acquire Mirati Therapeutics for a total of $4.8 billion. This merger deal entitles BMS to add KRAZATI (adagrasib), a best-in-class KRAS G12C inhibitor to its portfolio. The medicine is approved in the US for advanced KRAS G12C -mutated non-small cell lung cancer (NSCLC) in patients who have received at least one prior systemic treatment.

Drug Development 93

Drug Development 93

Express Pharma

OCTOBER 9, 2023

Chezgreen, a division of Cadila Pharmaceuticals, has introduced an under eye care cream for the Indian market. The Cahaya Naturals Under Eye Cream is formulated with L-Glutathione, Vitamin C and other natural extracts that are rich in antioxidants, to help regenerate damaged skin cells and keep skin hydrated. “ The Cahaya Naturals Under Eye Cream is made of natural ingredients that have no side effects.

96

96

Pharmaceutical Technology

OCTOBER 9, 2023

GSK and Chongqing Zhifei have signed an exclusive agreement for co-promoting the former’s shingles vaccine, Shingrix, in China.

Vaccines 110

Vaccines 110

The Pharmacist

OCTOBER 9, 2023

‘Long colds’ with similar respiratory impact as long Covid may be an ‘underestimated’ issue, a new study has concluded. By analysing 16 potential long Covid symptoms in participants from a UK population-based study, researchers have found that a previous Covid infection was ‘associated with increased prevalence and severity of a wide range of symptoms’.

93

93

Outsourcing Pharma

OCTOBER 9, 2023

Calliditas Therapeutics AB announced on Friday (October 5) that the European Medicines Agency (EMA) has issued a positive opinion on the companyâs drug, setanaxib in Alport Syndrome (AS).

88

88

The Pharmacist

OCTOBER 9, 2023

Urgent action is needed to help ‘turn the tide’ on high levels of burnout among pharmacists, those behind a new wellbeing report have warned. A lack of funding to support pharmacists and their teams is impacting staff wellbeing and more research is required to understand the ‘most effective measures’ to address workforce issues, the document […] The post Report lifts lid on high levels of burnout within community pharmacy appeared first on The Pharmacist.

Community Pharmacies 90

Community Pharmacies Documentation 90

European Pharmaceutical Review

OCTOBER 9, 2023

MSD’s WELIREG ® (belzutifan) has been accepted for use within NHS Scotland in adults who have von Hippel-Lindau (VHL) disease. This decision by the Scottish Medicines Consortium (SMC) relates to these patients who require therapy for VHL-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNETs), and for whom localised procedures are unsuitable or undesirable.

87

87

Outsourcing Pharma

OCTOBER 9, 2023

A 15-year partnership between Medidata, a Dassault SystÃmes company, and the National Cancer Institute (NCI) has been extended by five years. The NCI is part of the National Institutes of Health.

85

85

Pharmaceutical Technology

OCTOBER 9, 2023

Diabetes researchers oppose the regulation of islet transplantation as a biologic, following the approval of CellTrans’ Lantidra.

Diabetes 98

Diabetes 98

World Pharma News

OCTOBER 9, 2023

Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts will highlight the advances Pfizer is making in helping prevent and treat certain infectious diseases, particularly respiratory illnesses. This will include research featured in the IDWeek press program assessing the potential public health impact of ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company's bivalent resp

Vaccines 79

Vaccines Immunity Immunization 79

Outsourcing Pharma

OCTOBER 9, 2023

Contract research organization (CRO), Phastar, has had its net-zero target approved by SBTi which it hopes to achieve by adopting stringent sustainability standards.

82

82

pharmaphorum

OCTOBER 9, 2023

Alongside diagnosis: AI’s role in shaping health transformation outcomes Mike.

113

113

PharmExec

OCTOBER 9, 2023

Cosentyx is the first intravenous formulation interleukin-17A antagonist to focus on disease.

105

105

Outsourcing Pharma

OCTOBER 9, 2023

A new generative artificial intelligence (AI) tool has been launched by H1, a global healthcare data company and will have a 'profound impact on clinical trial diversity'.

75

75

PharmExec

OCTOBER 9, 2023

Supporters include Novartis Venture Fund, Brandon Capital, and more.

103

103

BioPharma Dive

OCTOBER 9, 2023

The agency rejected Alnylam’s application for approval of its medicine patisiran in people with a rare heart condition, setting back the company’s plans.

62

62

pharmaphorum

OCTOBER 9, 2023

Curio DTx hits mark in postpartum depression trial Phil.

103

103

Drug Patent Watch

OCTOBER 9, 2023

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com The post New tentative approval for Mylan Gmbh drug trastuzumab-dkst appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmafile

OCTOBER 9, 2023

GSK has announced that it has come to an exclusive agreement with Chingqing Zhifei Biological Products to co-promote GSK’s shingles vaccine, Shingrix, in China for an initial three years, with the option to extend the partnership further. This partnership is intended to combine the scale and expertise of the two companies and extend the availability […] The post GSK and Zhifei partner for shingles vaccine promotion in China appeared first on Pharmafile.

Vaccines 58

Vaccines 58

pharmaphorum

OCTOBER 9, 2023

GSK to lean on Zhifei for Shingrix and maybe Arexvy in China Phil.

96

96

Pharmafile

OCTOBER 9, 2023

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS will acquire Mirati for $58 per share, or a total value of $4.8bn. Mirati focuses on the discovery, design and delivery of breakthrough therapeutics for the treatment of various cancers. Through this acquisition, BMS will […] The post BMS acquires Mirati Therapeutics for $4.8bn appeared first on Pharmafile.

58

58